Sundia's Animal Facility Passed Client and Government Inspection

SHANGHAI, June 16 /PRNewswire-Asia/ -- Sundia MediTech Company, a
Shanghai-based integrated pharmaceutical contract research company, announced
today that its animal facility in Shanghai has passed the audit from a major
European Pharmaceutical Company. The Sundia management and staff are praised
for providing good facilities and programs for the care and use of laboratory
animals.
The inspection and audit took place in May. The entire animal facility
and life studies were inspected and audited. As stated in its official
approval letter: "Our overall impression of Sundia is very positive. The
personnel handling animals are well trained and engaged. All procedures are
well described in SOPs, and the site is very well organized." As a result of
an extensive on-site evaluation, the major European pharmaceutical company
determined that Sundia MediTech animal facility is committed to the highest
level of animal care and research practices.
Sundia has strong institutional commitment to the animal care and use
program. The Institutional Animal Care and Use Committee (IACUC) is led by
CEO,
Dr. Xiaochuan Wang. The state-of-art animal facility was designed by
SinoPharma Group Wuhan Institute. The operation of the animal facility has
followed the extensive Standard Operating Procedures (SOP) and guidelines, and
all records are well maintained. The animal facility was evaluated by Shanghai
Animal Management Committee, and the Permit for Using Laboratory Animals was
obtained in January this year.
"The success of passing the audit demonstrated our effort to provide
quality animal care for pharmaceutical research," said Dr. Jun Wang, Vice
President of Biology at Sundia MediTech. "We are very pleased to receive such
high praise from the leading major pharmaceutical company on the care and use
of laboratory animals. It demonstrates the quality of our laboratory testing
and the competence of our technicians," commented Dr. Xiaochuan Wang, CEO of
Sundia.
About Sundia MediTech.
Sundia MediTech is a leading integrated pharmaceutical contract research
organization (CRO) company. As a customer-focused company, Sundia MediTech
provides integrated drug discovery service to more than 80 top pharmaceutical
companies worldwide, ranging from early hit screening, biological service,
lead optimization, DMPK, candidate preclinical development, API manufacturer,
regulatory submission. For more information, please visit
http://www.sundia.com .
SOURCE Sundia Meditech Company, Ltd

Jun Wang, +86-21-5109-8642 x128, Sundia MediTech Company, Ltd